Search

Displaying results 3561 - 3570 of 6951 in total
  1. Drug

    Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB10990
    Approved

    toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for

  2. Drug

    Cannabidiol

    go.drugbank.com/drugs/DB09061
    ApprovedInvestigational

    While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. … It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS).

    Categories: Serotonin Receptor Agonists, Serotonin 5-HT1 Receptor Agonists
  3. Drug

    Perflubutane

    go.drugbank.com/drugs/DB12821
    ApprovedInvestigationalWithdrawn

    It is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease.

  4. Drug

    Epinastine

    go.drugbank.com/drugs/DB00751
    Approved

    Epinastine is used for the prevention of itching associated with allergic conjunctivitis.

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists
  5. Drug

    Uric acid

    go.drugbank.com/drugs/DB08844
    Investigational

    At present (August 2013), there is no approved formulation or indication for uric acid.

  6. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    approved COVID-19 mRNA vaccines, including the original Moderna COVID-19 vaccine ([elasomeran]), CX-052075 encodes only the immunodominant regions (NTD and RBD) of the SARS-CoV-2 spike protein, allowing for … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

  7. Drug

    Flupentixol

    go.drugbank.com/drugs/DB00875
    ApprovedInvestigationalWithdrawn

    It is approved for use in Canada and other countries around the world, but not in the US. … It is used for the management of chronic schizophrenia in patients whose main manifestations do not include excitement, agitation or hyperactivity.

    Categories: Adrenergic alpha-1 Receptor Antagonists, Dopamine D2 Receptor Antagonists
  8. Drug

    Fludrocortisone

    go.drugbank.com/drugs/DB00687
    ApprovedInvestigational

    Fludrocortisone is a synthetic mineralocorticoid used in conjunction with hydrocortisone to replace missing endogenous corticosteroids in patients with adrenal insufficiency. It is functionally similar to aldosterone, the body's primary ...

    Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain
  9. Drug

    Rucaparib

    go.drugbank.com/drugs/DB12332
    ApprovedInvestigational

    an androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval. … On December 17, 2025, the FDA granted regular approval to rucaparib for adults with a deleterious BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with

  10. Drug

    Tofersen

    go.drugbank.com/drugs/DB14782
    ApprovedInvestigational

    [L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.